Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
gevokizumab · 5 trials · 4 indications
The Australian/Canadian (AUSCAN) Osteoarthritis Hand Index is a self-report assessment of pain, stiffness, and function in patients with hand osteoarthritis.
| Arm | Type | Description |
|---|---|---|
| gevokizumab | EXPERIMENTAL | Solution for subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | - |
| low dose gevokizumab | EXPERIMENTAL | - |
| high dose gevokizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| gevokizumab | DRUG | - |
| Placebo | DRUG | Solution for subcutaneous injection |
Inclusion Criteria: * Autoimmune Inner Ear Disease with active deterioration in at least one ear * Failure to respond to a trial of high-dose corticosteroid therapy * Contraceptive measures adequate to prevent pregnancy during the study Exclusion Criteria: * Evidence of retrocochlear pathology (v...
Gevokizumab is an investigational monoclonal antibody developed by XOMA Royalty Corporation. It has been studied in Phase 2 clinical trials for several inflammatory and immune-related conditions, including acne vulgaris, autoimmune inner ear disease, osteoarthritis, and pyoderma gangrenosum. It is not approved and remains in clinical development.
Gevokizumab targets IL1B, also known as interleukin-1 beta. It is classified as a negative allosteric modulator of this target, meaning it binds in a way that reduces IL1B signaling rather than blocking the binding site directly. This mechanism is intended to dampen inflammatory pathways driven by IL1B.
Gevokizumab is developed by XOMA Royalty Corporation, which trades under the ticker XOMA. The company is the sponsor associated with the drug's clinical development program.
Gevokizumab is in Phase 2 clinical development. It is an investigational monoclonal antibody and is not FDA approved. The completed Phase 2 studies evaluated the drug across several indications, and no active trials are currently listed for this asset.
Gevokizumab has been evaluated in completed Phase 2 trials. These include NCT01950312 in corticosteroid-resistant autoimmune inner ear disease, NCT01882504 in pyoderma gangrenosum, and NCT01882491 and NCT01683396 in erosive osteoarthritis of the hand. All four studies were randomized, double-blind, and placebo-controlled, with a combined enrollment of 178 participants.
Gevokizumab was studied in Phase 2 trials for erosive osteoarthritis of the hand. Two completed studies, NCT01882491 and NCT01683396, enrolled 91 and 87 participants respectively and were randomized, double-blind, and placebo-controlled. The drug is investigational and has not been approved for osteoarthritis or any other indication.